Purdue’s marketing was far more successful than it predicted. The company had estimated it would earn $350 million from OxyContin in the first five years. The little opioid pill pulled in more than $2 billion in sales, accounting for 80 percent of Purdue’s revenue. The drug maker rushed to expand production.
